Whispered Prescriptions: Why British Patients Hide Their Weight-Loss Jabs From the People Closest to Them
Photo: Famous Players-Lasky Corporation / Paramount Pictures, Public domain, via Wikimedia Commons
Ask a consultant about the most common question they field before prescribing a GLP-1 receptor agonist, and it is rarely about side effects or eligibility. It is this: will people know I'm taking it?
That question says something uncomfortable about how Britain still regards obesity and its treatment. A patient starting insulin does not rehearse an explanation for their colleagues. A patient starting semaglutide often does.
The 'Cheating' Accusation
The most frequently reported criticism is a peculiar one: that medicating obesity is a shortcut, a form of dishonesty. Comment sections beneath even measured BBC coverage of Wegovy fill quickly with variations on the same theme — willpower, discipline, doing it properly.
This framing collapses under the slightest scrutiny. We do not describe statins as cheating for people who cannot lower cholesterol through diet alone. We do not accuse those taking antidepressants of bypassing genuine happiness. Yet GLP-1 medication attracts a moral judgement that other prescriptions simply do not, because it touches a condition — body weight — that the public still insists is a character issue rather than a chronic, biologically driven one.
The science is unambiguous. Obesity involves dysregulated appetite hormones, genetic predisposition and environmental factors far beyond individual control. GLP-1 agonists work by targeting precisely those mechanisms. Calling that cheating is rather like calling reading glasses cheating.
The Domestic Negotiation
What surprises many clinicians is where patients feel judgement most acutely: not from strangers online, but at their own kitchen tables. Partners who question the expense. Parents who mutter about 'taking the easy way'. Friends who interpret every mention of the injection as an implicit criticism of their own bodies.
Some patients respond by concealment — storing pens at the back of the fridge, injecting privately, inventing a digestive complaint to explain reduced appetite at family meals. This secrecy is understandable, but it is not harmless. Patients who hide their medication are less likely to report side effects promptly, less likely to maintain consistent follow-up appointments, and more likely to discontinue treatment abruptly when they hit a difficult patch.
Disclosure at Work
The workplace presents its own calculations. Declining the birthday cake 'on a health kick' invites comment; explaining you are on a prescribed appetite suppressant invites more. Many patients we hear from have settled on a middle path: vague honesty. 'I'm on a medically supervised plan' is accurate, defensible and requires no further detail.
Employers, for their part, have little business knowing. Weight-loss medication sits in the same privacy bracket as any other prescription. Those choosing full disclosure often report that anticipation was worse than reality — but the choice should remain theirs.
Why Attitudes Lag Behind the Medicine
Part of the gap is generational. GLP-1 agonists have moved from diabetes treatment to mainstream obesity care in under a decade; public understanding has not kept pace. Part of it is tabloid framing, which has consistently preferred the narrative of a celebrity scandal to one of legitimate chronic disease management.
But there is also a quieter factor: many of the loudest critics have watched a loved one struggle with their weight for decades and feel, perhaps, a flicker of defensiveness. Judgement is sometimes grief wearing a different coat.
A Case for Quiet Candour
We are not suggesting patients owe anyone an explanation. But where a trusted person exists — a partner, a close friend — disclosure tends to improve outcomes. Treatment adherence improves when someone at home understands why portions have shrunk and why the wine has stopped. Side effects are managed better when they are not hidden.
The medicine has moved into the twenty-first century. It is time the conversation around it did too. Nobody should need a safe word to discuss their own prescription.
